tiprankstipranks
Trending News
More News >
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
US Market
Advertisement

EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

Compare
924 Followers
See the Price Targets and Ratings of:

EYPT Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
EyePoint
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EYPT Stock 12 Month Forecast

Average Price Target

$33.00
▲(135.55% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is $33.00 with a high forecast of $68.00 and a low forecast of $18.00. The average price target represents a 135.55% change from the last price of $14.01.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","21":"$21","37":"$37","53":"$53","69":"$69"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,21,37,53,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.71,14.193846153846154,18.677692307692308,23.161538461538463,27.645384615384614,32.129230769230766,36.61307692307692,41.096923076923076,45.58076923076923,50.06461538461538,54.54846153846153,59.03230769230769,63.51615384615384,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.71,11.501538461538463,13.293076923076924,15.084615384615386,16.876153846153848,18.667692307692306,20.45923076923077,22.25076923076923,24.042307692307695,25.833846153846153,27.625384615384615,29.416923076923077,31.20846153846154,{"y":33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.71,10.34769230769231,10.985384615384616,11.623076923076924,12.260769230769231,12.89846153846154,13.536153846153848,14.173846153846155,14.811538461538461,15.44923076923077,16.086923076923078,16.724615384615383,17.362307692307695,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.71,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.06,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.76,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.45,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.65,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$68.00Average Price Target$33.00Lowest Price Target$18.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on EYPT
Mizuho Securities
Mizuho Securities
$26$28
Buy
99.86%
Upside
Reiterated
08/14/25
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities…and a high degree of confidence in the likelihood of Duravyu's P3 success, we reiterate our OP rating on EYPT.
JonesTrading
$41
Buy
192.65%
Upside
Reiterated
08/11/25
Analysts' Top Healthcare Picks: EyePoint Pharmaceuticals (EYPT), Axsome Therapeutics (AXSM)Wereiterate Buy & our $41 PT
Scotiabank Analyst forecast on EYPT
Scotiabank
Scotiabank
$18
Buy
28.48%
Upside
Reiterated
08/07/25
Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)
Guggenheim Analyst forecast on EYPT
Guggenheim
Guggenheim
$68
Buy
385.37%
Upside
Reiterated
08/06/25
With rapid execution in pivotal study enrollment, we reiterate our Buy rating and set a $68 price target.
TD Cowen
$20$25
Buy
78.44%
Upside
Reiterated
08/06/25
EyePoint Pharmaceuticals: Promising Phase III Trials and Market Potential for Long-Acting TKI
RBC Capital Analyst forecast on EYPT
RBC Capital
RBC Capital
$28
Buy
99.86%
Upside
Reiterated
08/06/25
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Surgery Partners (NASDAQ: SGRY)
H.C. Wainwright Analyst forecast on EYPT
H.C. Wainwright
H.C. Wainwright
$22$23
Buy
64.17%
Upside
Reiterated
08/06/25
EyePoint Pharmaceuticals: Promising Phase 3 Trial Progress and Strategic Advancements Justify Buy Rating
J.P. Morgan Analyst forecast on EYPT
J.P. Morgan
J.P. Morgan
$26
Buy
85.58%
Upside
Reiterated
05/27/25
J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
Cantor Fitzgerald Analyst forecast on EYPT
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
02/05/25
EyePoint Pharmaceuticals (EYPT) decline "makes no sense", says Cantor FitzgeraldCantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) following VERONA data. Kim said the selloff in the stock "makes no sense.
Citi
$33
Buy
135.55%
Upside
Initiated
01/07/25
EyePoint Pharmaceuticals: Positioned for Growth with DURAVYU in the wAMD Market
Robert W. Baird Analyst forecast on EYPT
Robert W. Baird
Robert W. Baird
$38$33
Buy
135.55%
Upside
Reiterated
11/11/24
EyePoint price target lowered to $33 from $38 at BairdEyePoint price target lowered to $33 from $38 at Baird
Capital One Financial Analyst forecast on EYPT
Capital One Financial
Capital One Financial
$35
Buy
149.82%
Upside
Assigned
10/28/24
EyePoint Pharmaceuticals' Positive Clinical Data Boosts Buy Rating Amid Promising Eye Disease Therapies
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on EYPT
Mizuho Securities
Mizuho Securities
$26$28
Buy
99.86%
Upside
Reiterated
08/14/25
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities…and a high degree of confidence in the likelihood of Duravyu's P3 success, we reiterate our OP rating on EYPT.
JonesTrading
$41
Buy
192.65%
Upside
Reiterated
08/11/25
Analysts' Top Healthcare Picks: EyePoint Pharmaceuticals (EYPT), Axsome Therapeutics (AXSM)Wereiterate Buy & our $41 PT
Scotiabank Analyst forecast on EYPT
Scotiabank
Scotiabank
$18
Buy
28.48%
Upside
Reiterated
08/07/25
Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)
Guggenheim Analyst forecast on EYPT
Guggenheim
Guggenheim
$68
Buy
385.37%
Upside
Reiterated
08/06/25
With rapid execution in pivotal study enrollment, we reiterate our Buy rating and set a $68 price target.
TD Cowen
$20$25
Buy
78.44%
Upside
Reiterated
08/06/25
EyePoint Pharmaceuticals: Promising Phase III Trials and Market Potential for Long-Acting TKI
RBC Capital Analyst forecast on EYPT
RBC Capital
RBC Capital
$28
Buy
99.86%
Upside
Reiterated
08/06/25
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Surgery Partners (NASDAQ: SGRY)
H.C. Wainwright Analyst forecast on EYPT
H.C. Wainwright
H.C. Wainwright
$22$23
Buy
64.17%
Upside
Reiterated
08/06/25
EyePoint Pharmaceuticals: Promising Phase 3 Trial Progress and Strategic Advancements Justify Buy Rating
J.P. Morgan Analyst forecast on EYPT
J.P. Morgan
J.P. Morgan
$26
Buy
85.58%
Upside
Reiterated
05/27/25
J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
Cantor Fitzgerald Analyst forecast on EYPT
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
02/05/25
EyePoint Pharmaceuticals (EYPT) decline "makes no sense", says Cantor FitzgeraldCantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) following VERONA data. Kim said the selloff in the stock "makes no sense.
Citi
$33
Buy
135.55%
Upside
Initiated
01/07/25
EyePoint Pharmaceuticals: Positioned for Growth with DURAVYU in the wAMD Market
Robert W. Baird Analyst forecast on EYPT
Robert W. Baird
Robert W. Baird
$38$33
Buy
135.55%
Upside
Reiterated
11/11/24
EyePoint price target lowered to $33 from $38 at BairdEyePoint price target lowered to $33 from $38 at Baird
Capital One Financial Analyst forecast on EYPT
Capital One Financial
Capital One Financial
$35
Buy
149.82%
Upside
Assigned
10/28/24
EyePoint Pharmaceuticals' Positive Clinical Data Boosts Buy Rating Amid Promising Eye Disease Therapies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering EyePoint Pharmaceuticals

1 Month
xxx
Success Rate
8/16 ratings generated profit
50%
Average Return
+4.41%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +4.41% per trade.
3 Months
xxx
Success Rate
10/16 ratings generated profit
63%
Average Return
+19.96%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +19.96% per trade.
1 Year
Success Rate
7/10 ratings generated profit
70%
Average Return
+19.30%
reiterated a buy rating last month
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +19.30% per trade.
2 Years
xxx
Success Rate
8/10 ratings generated profit
80%
Average Return
+29.86%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +29.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EYPT Analyst Recommendation Trends

Rating
Mar 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
12
20
18
15
12
Buy
2
2
0
0
0
Hold
3
6
10
14
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
28
28
29
23
In the current month, EYPT has received 12 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. EYPT average Analyst price target in the past 3 months is 33.00.
Each month's total comprises the sum of three months' worth of ratings.

EYPT Financial Forecast

EYPT Earnings Forecast

Next quarter’s earnings estimate for EYPT is -$0.77 with a range of -$0.94 to -$0.67. The previous quarter’s EPS was -$0.85. EYPT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year EYPT has Outperformed its overall industry.
Next quarter’s earnings estimate for EYPT is -$0.77 with a range of -$0.94 to -$0.67. The previous quarter’s EPS was -$0.85. EYPT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year EYPT has Outperformed its overall industry.

EYPT Sales Forecast

Next quarter’s sales forecast for EYPT is $3.46M with a range of $0.00 to $11.71M. The previous quarter’s sales results were $5.33M. EYPT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year EYPT has Outperformed its overall industry.
Next quarter’s sales forecast for EYPT is $3.46M with a range of $0.00 to $11.71M. The previous quarter’s sales results were $5.33M. EYPT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year EYPT has Outperformed its overall industry.

EYPT Stock Forecast FAQ

What is EYPT’s average 12-month price target, according to analysts?
Based on analyst ratings, EyePoint Pharmaceuticals Inc’s 12-month average price target is 33.00.
    What is EYPT’s upside potential, based on the analysts’ average price target?
    EyePoint Pharmaceuticals Inc has 135.55% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is EYPT a Buy, Sell or Hold?
          EyePoint Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is EyePoint Pharmaceuticals Inc’s price target?
            The average price target for EyePoint Pharmaceuticals Inc is 33.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $68.00 ,the lowest forecast is $18.00. The average price target represents 135.55% Increase from the current price of $14.01.
              What do analysts say about EyePoint Pharmaceuticals Inc?
              EyePoint Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of EYPT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis